1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical Co., Ltd.

20.80
EUR
0.00
(0.00%)
1.06BMarket Cap
Nov 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1,203.29
1,401.77
1,647.64
1,726.28
1,898.63
2,135.86
2,243.14
3,147.46
3,365.09
4,243.22
4,630.98
5,273.78
5,560.74
- -
Basic EPS, GAAP
117.52
218.06
154.18
113.31
131.99
273.83
294.72
283.62
323.35
44.72
328.59
385.71
106.66
- -
Free Cash Flow per Basic Share
-1.45
-111.19
-208.38
-222.99
78.38
155.42
294.54
43.26
173.79
-567.33
-632.13
-158.91
128.01
- -
Dividend per Share
25.01
25.01
35.21
31.66
31.64
31.68
42
44.01
48.99
62.98
59.98
59.99
79.98
- -
Book Value per Share
1,179.66
1,373.86
1,434.79
1,522.97
1,624.07
1,864.88
2,126.68
2,369.18
2,685.15
2,781.14
3,167.24
3,486.37
3,617.93
- -
Tangible Book Value per Share
1,161.89
1,356.92
1,411.89
1,484.48
1,584.72
1,835.01
1,811.06
2,065.16
1,505.53
1,705.52
2,139.53
2,555.16
3,076
- -
Basic Weighted Avg Shares
51
51
50
49
49
49
49
49
49
49
49
49
49
49
Sales/Revenue/Turnover
61,351
71,470
82,115
84,949
93,430
105,104
110,384
154,900
165,615
208,859
227,934
259,594
273,710
- -
Operating Margin (%)
12.56
15.54
13.56
8.09
12.46
15.19
14.62
12.86
11.6
2.64
7.74
8.95
8.44
- -
Depreciation Expense
5,407
5,724
7,329
7,980
8,173
8,340
8,285
10,425
10,954
19,409
17,888
20,099
22,837
- -
Net Income, GAAP
5,992
11,118
7,684
5,576
6,495
13,475
14,503
13,958
15,914
2,201
16,173
18,986
5,250
- -
Effective Tax Rate (%)
31.14
26.88
22.41
22.95
33.95
28.65
29.97
25.47
28.46
52.2
33.88
27.89
60.11
- -
Profit Margin (%)
9.77
15.56
9.36
6.56
6.95
12.82
13.14
9.01
9.61
1.05
7.1
7.31
1.92
- -
Working Capital
32,037
35,588
63,870
51,951
58,296
71,029
51,361
85,774
51,791
104,461
137,600
159,367
170,476
- -
LT Debt
16,620
18,468
53,502
54,309
59,849
58,442
51,664
74,098
79,194
150,314
189,838
206,878
196,164
- -
Total Equity
60,146
70,047
70,605
74,944
79,919
91,769
104,663
116,598
132,168
136,893
155,892
171,624
178,103
- -
Return on Invested Capital (%)
6.78
9.08
7.71
4.03
5.45
7.37
6.46
7.61
5.74
0.91
3.5
4.33
2.26
- -
Return on Capital (%)
7.95
12.92
7.09
4.36
4.74
8.98
8.54
7.35
6.82
0.88
5.11
5.29
1.52
- -
Return on Common Equity (%)
10.35
17.08
10.93
7.66
8.39
15.7
14.77
12.62
12.79
1.64
11.05
11.59
3
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
31,202
30,571
- -
LT Borrowings
192,069
183,335
- -
LT Finance Leases
12,992
12,829
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
49
49
Market Capitalization
141,798
195,044
186,516

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
255,984
267,343
- -
Cash, Cash Equivalents & STI
49,576
45,306
- -
Accounts Receivable, Net
56,934
63,283
- -
Inventories
118,505
123,425
- -
Total Current Liabilities
91,282
96,867
- -
Payables & Accruals
- -
- -
- -
ST Debt
31,202
30,571
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
8.93%
3.78%
Free Cash Flow
-39.57%
-73.75%
-180.55%
Net Income, GAAP
60.81%
101.54%
-72.35%
Sales/Revenue/Turnover
13.28%
12.3%
5.44%
Total Cash Common Dividend
9.47%
13.69%
33.32%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
259,594
2026
- -
- -
- -
- -
273,710
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
385.71
2026
- -
- -
- -
- -
106.66
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
59.99
2026
- -
- -
- -
- -
79.98
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Itsuro Yoshida
Full Time Employees
4,923
Sector
Health technology
Industry
Pharmaceuticals: major
Address
2-11, Shinbashi-cho Kadoma Japan 571-8580
IPO Date
Apr 5, 2004
Website
towayakuhin.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Towa Pharmaceutical Co., Ltd. (4553.T) manufactures and sells generic ethical drugs in Japan and overseas. The company, founded in June 1951 and incorporated in April 1957, is headquartered in Kadoma, Osaka, Japan, and operates plants including Osaka, Okayama, and Yamagata facilities; it lists on the Prime section of the Tokyo Stock Exchange. Towa offers over 730 products covering therapeutic areas such as lifestyle-related diseases including hypertension and diabetes, digestive system diseases, nervous system diseases, allergic diseases, vitamins, antibiotics, and oncology products; formulations include tablets, capsules, injectables, patches, and eye drops. Towa maintains domestic sales to medical institutions, wholesalers, and manufacturers through sales offices, while its overseas segment handles generic sales, contract research, and development and manufacturing via subsidiaries. Key subsidiaries encompass J-DOLPH Pharmaceutical for ethical drugs, Daichi Kasei for active pharmaceutical ingredients and intermediates, Greencaps Pharmaceutical for soft capsules, Towa Pharma International Holdings as EU/US regional headquarters, Protosera for disease risk testing and R&D support, Sunsho Pharmaceutical for health foods and OEM manufacturing, T Square Solutions for healthcare IT services, and Kyushu Iyaku for ethical and quasi drugs. Recent developments include approval for six generic ingredients and ten new items in August 2024, enhancing the product lineup; expansion of B2B business to 39 countries; initiation of global product development; and promotion of joint ventures leveraging overseas manufacturing technologies. Towa is strengthening its overseas generics presence through portfolio enrichment in gastrointestinal, metabolic, circulatory, skin, urology, and infectious disease areas, alongside construction of distribution centers and capacity increases to 17.5 billion tablets annually. Overseas, Towa International advances high-containment area investments exceeding 10 million euros at its Barcelona plant for highly potent oncology and immunosuppressant medicines, targeting operational status in 2026 with enhanced production capacity.

Company News

Company News APIChatGPT

  • defenseworld.net

    Financial Contrast: Towa Pharmaceutical (OTCMKTS:TWAPF) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX)